Index

Note: page numbers in italic refer to figures; those in bold to tables or boxes.

AABB (formerly American Association of Blood Banks) 220, 221, 329
Biovigilance Inter-organizational Task Force 221, 222, 223–4
cell and tissue vigilance 333, 336–7
tissue Task Force 336
ABO blood grouping 118–19
errors 119–20
ABO-incompatible transfusions 9, 347
achievements of hemovigilance 298
Australia 212, 213
blood administration errors 70
errors in collection of blood component 69
France 152–4, 155, 156
laboratory errors 120
sample collection errors 132, 133
UK 127, 141
achievements through hemovigilance 10, 281–301
actions and measures triggered 292–6
methods of data collection 283–4
outcomes and achievements 296–9
results of data analysis 288–99
UK SHOT data 284–8, 289
active hemovigilance 15
active surveillance 150, 326
acute hemolytic transfusion reactions (AHTRs) 298, 354
see also ABO-incompatible transfusions
acute hypervolemic hemodilution (AHH) 307
acute normovolemic hemodilution (ANH) 307–8, 309, 310
acute transfusion reactions (ATR) 291
achievements of hemovigilance 287–8, 298
monitoring errors 136
UK SHOT data 169, 172, 204, 287–8
administration, blood 69–71, 134–6
case studies 131–6
checks before 129, 134–6, 139
documentation 69
errors 135, 136–6
monitoring 69–71, 71, 129, 136–7
staff training 69–70, 137–8
administration of wrong blood 171
adverse events (AE) 9
Arab Hemovigilance Network 227, 229
Australian system 214
autologous transfusion 309
definitions 6–7, 7, 345, 353
in donors 347–50
human cell, tissue, and product (HCT/P)-related 331–3, 335–6
in recipients
developing countries 265–7, 266
glossary of terms 346–7
Japanese system 361–2
rates 127–8, 141
reporting of error-based 127–8
UK SHOT scheme 169–72
under-reporting 137
US surveillance 221–3, 329–30
see also transfusion reactions reportable 13, 13
Europe 238, 240, 254–5
reporting see reporting of events
serious see serious adverse events
solid organ transplant-related 331, 333–4
adverse reactions (AR)
definition 7, 7, 345, 353
in donors see donor adverse reactions
in recipients see transfusion reactions reportable 13, 13
European Union 238, 240
reporting see reporting of events
serious see serious adverse reactions
adverse transfusion events (ATEs)
Canada 195–6, 196, 197
defined 191
see also adverse events
Advisory Committee on Blood Safety and Availability (ACBSA), US 328
Advisory Committee on Safety of Blood, Tissues and Organs (SaBTO), UK 175
affaire du Sang, L’ (Casteret) 147, 148
AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé) 10, 150, 150
centralized structure 15
communication of results 151–2
governance 14
see also France
alarms, storage systems 58
allergic (transfusion) reactions
Canada 196, 197
definition 355
the Netherlands 187
allergy, local (in donors) 348, 364
alloimmunization 9, 291
All Wales Cell Salvage Database 314, 315, 316
alternatives to blood components 10, 305–21
hemovigilance 13, 314–18
techniques 306–14
American Red Cross (ARC) 220
America’s Blood Centers (ABC) 220
anaphylactic reactions 9, 355
Canada 196, 197
European reports 246, 246
intravenous iron 311
the Netherlands 187
prevention in Japan 165, 166
anemia
erthropoietin therapy 312–13
iron therapy 311
annual reports, published 283–4
anti-D immunoglobulin 169–70
apheresis 77, 344
analysis of complications 92
donation process 81
donor complications 24, 94, 365
appropirate transfusion 10–11, 61–8
guidelines and policies 62–4
implementing guidelines 65–6

appropriate transfusion (Continued)
jobs and responsibilities 64–5
monitoring and assessment 65
see also inappropriate and unnecessary transfusion
aprotinin 313
Arab Hemovigilance Network (AHN) 226–32, 232
basic guidelines and requirements 228
establishing 228–32
policies 227
website 229, 230, 231
arm
anatomy, analysis 92, 93
painful 348, 349, 364, 366
arterial puncture 348, 349, 363
grading of severity 366
Assistant Secretary of Health (ASH), US 328
Association of Anesthetists of Great Britain (AAAGB) 62
audits
appropriate blood use 65
blood component preparation 48–9, 108–9
clinical transfusion practice 136–7
returned blood components 68, 69
Australia 209–19
blood sector 209–11
hemovigilance system 209–19
communication/reporting 215
context 209–11
lessons learned 215, 216–17
major regional programs 211–13
national arrangements 213–15
research opportunities 215–17
Australian and New Zealand Society of Blood Transfusion (ANZSBT) 62, 210, 218
Australian Commission for Safety and Quality in Health Care (ASCHQC) 211
Australian Institute of Health and Welfare (AIHW) 214, 215
Australian Red Cross Blood Service 210, 214–15
autologous transfusion 306–10, 344
possible problems 309–10
techniques 306–9
UK SHOT scheme 171, 309, 314–18, 317, 318, 319
auto-sterilization 102
bacterial contamination
Australia 214–15
incoming whole blood, for processing 102
minimization 100
New Zealand preventive measures 293
processed blood products 48
quality control testing 117–18
bacterial infections, transfusion-transmitted see transfusion-transmitted bacterial infections
benefits of transfusion 322, 323
biologic-based products/technologies 327
biovigilance 11, 326–40
background of need 327–8
Canada 202, 335
coordinating public health and approach to risk 328, 328
definition 320, 326
developing systems for cells, tissues and organs 334–7
emerging threat assessment 337–8
Europe 250, 251, 334–5
mandates for comprehensive programs 338–9
United States 220–5, 328–33, 335–7
blame-free (no-fault) reporting 14, 26, 256
bleeding disorder patients, monitoring in US 330
blood, defined 343
Blood, Organ, and Tissue Senior Executive Council (BOTSEC), US 328
blood bank hemovigilance officers, French system 150
blood bank laboratory, monitoring optimal use 65
blood banks, hospital see hospital blood banks
Blood-borne Pathogens Surveillance Project (BBPSP), Canada 201
blood collection
limits on volume 95
methods 77
blood components (BC) 38
definitions 6, 343
initial focus on 12
labeling 42
management of nonconforming 43
preparation see preparation of blood components
product nonconformities (indicator) 47–8
returned 59
risks 38
storage see storage
traceability see traceability
see also blood products
blood donation 77–98
autologous 306–7
completion rates and draw times 83
developing countries 263
process 21–2, 22, 81–3, 82
settings 81–3
see also donor (hemovigilance)
blood donors see donors
blood establishments (BEs) 8
actions and measures taken 293, 293–5
defined 7, 344
developing countries 262–4, 265
donor hemovigilance systems 21–35,
78–80
European requirements 241–3
hemovigilance procedures in Greece 54–9
issuing of blood components 121, 121–3
outcomes and achievements 296, 297
preparation of blood components 36–51, 99–112
processes 21–2, 22
protection of identity 29
quality management systems 294
risks and problems identified 289–90, 290
testing of donor blood 113–21
blood group serology- compatibility testing 56–7, 118–21
error management 120–1
errors 118, 119–20
guidelines 56–7
hemovigilance procedures 57
procedures 119
quality issues 118–19
blood Law, Japan 160
blood loss, minimizing 305
Blood Matters program, Australia 210, 211, 212
blood packs/bags
fault monitoring 107
incoming, for processing 41, 102–3
blood products (BP)
definitions 6, 344
labeling 42
management of nonconforming 43
manufacture
closed system 42
open system 42
planning 40
poor seals 48
procedures 41–2
see also preparation of blood components
nonconformities (quality indicator) 47–8
packaging 48, 58
quality control 45–8
risks 38
storage see storage
traceability see traceability
infected 116–17
see also blood components
BloodSafe program, South Australia (SA) 213
Blood Safety and Quality Regulations 2005 (BSQR), UK 67, 128, 169
Blood Scandal (L’affaire du Sang) (Casteret) 147, 148
Blood Service Headquarters (BSHQ), Japan 160, 161, 162
blood transfusion
benefits and risks 322
clinical activities see clinical transfusion activities
Index

372  Index

documentation (Continued)
release of components 108, 121–2
transportation of blood components 123–4
see also data; standard operating procedures
donation see blood donation
Donation after Cardiac Death (DCD) 334
donation site 367
donor adverse reactions (complications related to blood donation) 7, 22–5
categories 23, 78, 78, 360–5
causes 23
codes 85, 85–6
data
analysis and reporting 80, 88–92, 89, 91
denominators 32–3, 86–8, 88
gathering 25, 29, 78–9
management 83–6, 84, 85
need for better 34
uses 31–2, 32, 33–4, 80–1
validation 30–1, 31
definitions 22–3
delayed 23, 24–5
European Union 32, 246–7
glossary of terms 347–50
goals of donor vigilance 78
imputability 24
gradation 349, 367
ISBT standard for surveillance 360–8
Italian system 207
Japanese rates 164–5, 165, 165
long-term 24
monitoring 31–2
non-severe (non-serious) 24–5, 349, 366–7
data capture 86
monitoring and assessment 31, 32
prevention 94–6
recognizing and treating 25, 25
reporting 31–2, 88–92, 89
risk factors 23
severe (serious) 24–5, 349
data capture 86
defined 23, 366
monitoring and assessment 31, 32
severity, grading 349–50, 366–7
specific 24
staff responsibilities 30, 31
standard operating procedures 30
statistics 23, 77
variations in rates 34
Donor and Recipient Complications
Program (DRCP), American Red Cross 220
Donor Hemovigilance System, US 86–8, 87, 88, 90, 223–4
donor incident forms 84
donors
adverse events 347–50
adverse reactions see donor adverse reactions
confidentiality of information 29
counseling 28
defined 344
developing countries 262
education/information 95
errors in care 25–6, 26
paid 159
position during donation 90
post-donation information 27, 27, 27–8
pre-donation screening 81, 102
risks and problems 289–90
screening for infection 54–5, 54–5
selection 81, 102, 296–7
voluntary and nonremunerated 101, 344
see also blood donation
donor sites (centers), fixed 81–3
donor (hemo)vigilance 8, 77–98
donor adverse reactions (complications related to blood donation) 7, 22–5
categories 23, 78, 78, 360–5
causes 23
codes 85, 85–6
data
analysis and reporting 80, 88–92, 89, 91
denominators 32–3, 86–8, 88
gathering 25, 29, 78–9
management 83–6, 84, 85
need for better 34
uses 31–2, 32, 33–4, 80–1
validation 30–1, 31
definitions 22–3
delayed 23, 24–5
European Union 32, 246–7
glossary of terms 347–50
goals of donor vigilance 78
imputability 24
gradation 349, 367
ISBT standard for surveillance 360–8
Italian system 207
Japanese rates 164–5, 165, 165
long-term 24
monitoring 31–2
non-severe (non-serious) 24–5, 349, 366–7
data capture 86
monitoring and assessment 31, 32
prevention 94–6
recognizing and treating 25, 25
reporting 31–2, 88–92, 89
risk factors 23
severe (serious) 24–5, 349
data capture 86
defined 23, 366
monitoring and assessment 31, 32
severity, grading 349–50, 366–7
specific 24
staff responsibilities 30, 31
standard operating procedures 30
statistics 23, 77
variations in rates 34
Donor and Recipient Complications
Program (DRCP), American Red Cross 220
Donor Hemovigilance System, US 86–8, 87, 88, 90, 223–4
donor incident forms 84
products and processes 21–2, 22
training and assessment 33
United States see Donor Hemovigilance System, US
drug registration (DR) 105
drug safety (DS) 105
Dutch Healthcare Inspectorate (IGZ) 180
Dutch hemovigilance system 180–90
see also Transfusion Reactions in Patients (TRIP)
Dutch Institute for Healthcare Improvement (CBO) 180
education see training
emerging infectious diseases (EIDs) 337–8
epidemic intelligence 249
epidemiological surveillance 149–50
epidemiological terms 346
equipment, blood component preparation 39, 103, 103–4
errors/deviations
achievements of hemovigilance 298
blood group serology-compatibility testing 118, 119–21
blood product manufacture 43, 48, 103, 104, 105–7, 106
donor care 25–6, 26
European Commission (EC) 237, 249, 250
European Center for Disease Prevention and Control (ECDC) 247, 249
European Commission (EC) 237, 249, 250
European Committee on Blood Transfusion (CD-P-TS) 235
European Community and Control (ECDC) 247, 249
European Community 235–52
EU Directives 7, 15, 237–44
89/388/EEC 236
2002/98/EC (Blood Directive; Mother Directive) 52, 237–9, 254
scope of reporting 238, 239
UK SHOT scheme 168, 173–4
2004/33/EC 239–40
2005/61/EC 240–2
2005/62/EC 242–3
Daughter 238–43
production of blood components 161, 240–2
transposition by member states 243–4
European Directorate for the Quality of Medicines and HealthCare (EDQM) 235
iron deficiency 92, 94
deficiency anemia 311
therapy 311
irradiated blood 159, 294
provision of 66–7
UK SHOT scheme 285
ISBT see International Society of Blood Transfusion
ISBT 128 coding 333
ISO 9000 series of standards 36
issuing 121, 121–3
achancements of hemovigilance 298
defined 344
European requirements 241
Greek system 59
notification of adverse events 122–3
ISTARE database 253
IT see information technology
Italian hemovigilance system 204–8
aims and responsibilities 207–8
computerized system 205–6
framework 206–7
governance 205
Japan Council for Quality Health Care
Japanese Hemovigilance System 159–67
advantages and limitations 166
adverse reactions 164–5
concepts and methodology 162–3
data analysis and feedback 163
errors and near-misses 163–4
evaluation 163
governance 161
history 159–60
legal basis 160
look-back studies 163
reportable events/reporting system 161–2
setting up 160–1
usefulness of data 165–6
Japanese Red Cross Society (JRCS)
159–62, 163, 165
The Joint Commission (TJC), US 221, 336
junior doctors
inappropriate and unnecessary
transfusions 129, 131
patient handovers 138
professional responsibility 139–40
training and education 137
Krever Commission (1977) 192, 201
labeling
autologous blood donations 310
human tissues and cells 332–3
issued blood products 123
processed blood products 42
shipping containers 123
labile blood products (LBP), France 150, 151
numbers issued 152, 152, 153, 154
see also blood products
laboratory errors
incorrect blood component transfused (IBCT) 119–20
UK SHOT scheme 171
Laboratory Information Management System (LIMS) 67
legal framework 7, 15
developing countries 268
European Union (EU) 7, 237–44
Japan 160
production of blood products 100–1
leucodepletion 294, 298
leucodepletion filters (LDF), salvaged blood 316
look-back defined 345
Japanese system 163
look-back procedures 116–17
defined 345
Greece 56, 117
Los Angeles County + University of Southern California (LAC + USC) Healthcare Network, Blood Transfusion Assessment Tool 70–1, 71
Luxembourg 282
machinery, blood component preparation 39, 103, 103–4
major morbidity, UK SHOT scheme 172
male-only donor plasma 298
preparation 41
prevention of TRALI 10, 186, 186–7, 286
manufacturers, governance role 15
massive transfusion protocol (MTP) 63–4
monitoring adherence 65
materials, blood component preparation 39
materiovigilance 39
maximum surgical blood ordering schedule (MSBOS) 62, 63
media, mass 177
medical decision (to transfuse) 61–8, 128, 129–32
guidelines and standards 62–4
implementing guidelines 65–8
jobs and responsibilities 64–5
monitoring and assessment 65
training and education 68
see also indications for transfusion
Medical Event Reporting System for Transfusion Medicine (MERS-TM), New York 220
Medical Product Safety Network (MedSun), US 335–6
medical representatives (MRs), Japan 159, 161, 162
medical staff
implementing transfusion guidelines 64, 65, 66
inappropriate and unnecessary transfusions 64, 129, 131
ordering errors 134
professional responsibility 139–40
sampling errors 132, 133
training and education 137–8
Medicines and Healthcare products
Regulatory Agency (MHRA), UK 169, 173–4
midwives, sampling errors 132, 133
Ministry of Health (MoH), Italian 204–5
Ministry of Health, Labour and Welfare (MHLW), Japanese 160–1, 162
mobile donor buses 83
models, hemovigilance 12–16
monitoring and assessment
blood administration 69–71, 71, 129, 136–7
blood component preparation 45–9, 108–9
donor vigilance 30–4
medical decision and ordering 65
monitoring and evaluation (M&E) 326–7
mortality, transfusion recipients 323
multivariate analysis, donor vigilance data 90–2
muscle tensing exercises 95
national authorities
blood transfusion 227
monitoring optimal blood use 65
National Blood Authority (NBA), Australia 210, 213–14, 218
National Blood Center (NBC), Italy 204, 205
National Blood Transfusion Committee (NBTC), UK 137, 175
National Comparative Audits, UK 136–7
National Health and Medical Research Council (NHMRC), Australia 214, 218
National Healthcare Safety Network (NHSN), US 221–3, 223, 330
National Health Service Blood and Transplant (NHSBT), UK 172, 176
National Health Service Blood and Transplant/Health Protection Agency (NHSBT/HPA) Epidemiology Unit, UK 173
National Health Service (NHS) Connecting for Health (CFH), UK 173
National Heart, Lung and Blood Institute (NHLBI), US 330, 337
National Hemovigilance Office (NHO), Arab Hemovigilance Network 227
national hemovigilance systems 8
Australia 213–15
Canada 191–203
developing countries 260–2, 261, 262
Index

national hemovigilance systems
(Continued)
donor vigilance data management 84–6, 85
France 130, 150–6, 168
Greece 52–60
Italy 204–8
Japan 159–67
the Netherlands 180–90
requirements 227
UK 168–79
United States 220–5
National Institute of Health (ISS), Italy 204
National Marrow Donor Program (NMDP), US 331, 337
National Patient Safety Agency (NPSA), UK 137–8, 175
national transfusion guidelines, establishing 62–3
National Working Group for Transfusion Error Surveillance System (NWGTESS), Canada 200
National Working Group for Transfusion Transmitted Injuries Surveillance System (NWGTISS), Canada 194–5
National Working Party for Data Review (NWPDR), Canada 196–8
near-misses
Canadian system 198–200, 199
definitions 7, 7, 188, 345, 353
Italian system 206
Japanese system 163–4
the Netherlands 188–9, 189
rates in Greece 113
UK SHOT scheme 170–1
see also errors/deviations; incidents
needle-related injuries
data analysis 91, 91–2
minimizing 94, 95–6
nerve injury 348, 364
data analysis methods 91, 91–2
nerve irritation 348, 363
Netherlands 180–90
achievements through hemovigilance 292
see also Transfusion Reactions in Patients
New South Wales (NSW) Blood Watch program 213
New York State Department of Health 221
New Zealand National Haemovigilance Programme 289, 292–3, 296
no-fault (blame-safe) reporting 14, 26, 256
non-governmental organizations (NGOs), Canadian hemovigilance system 194
notification of events see reporting of events
nucleic acid amplification technology (NAT) testing 114, 293–4
Greece 55
Japan 165
numerator 346
nursing staff
implementing transfusion guidelines 64
inappropriate and unnecessary transfusion 130
professional responsibility 140
sampling errors 132, 133
training and education 137–8
obstetrics, intra-operative cell salvage (ICS) 309
official contact persons (OCPs) 14, 15
open system of manufacture 42
optimal blood use see appropriate transfusion
ordering 61–8, 128–9
passive surveillance 150, 326
passive hemovigilance 15
permanent blood stem cell (PBSC) donors 337
personnel
blood administration 69–70
blood component preparation 37–8
qualifications 39
tasks and responsibilities 44–5, 107–8
training and assessment 50
donor hemovigilance
tasks and responsibilities 30, 31
training 33
overseeing optimal blood use 64–5
professional responsibility 139–40
training see training
see also medical staff; nursing staff
Pharmaceutical Affairs Law (1960), Japan 160, 161, 162
pharmacovigilance 5, 236
phlebotomists, sampling errors 133
phlebotomy 81
physical counter-pressure maneuvers 95
physicians see medical staff
planning
blood component manufacture 40
blood product quality control 45–6
plasma 343
derived products, international hemovigilance 257–8
processing 21–2, 294
recovered 343
as starting material 100–1
plasma fractionation institute, look-back procedures 116
plasma master file (PMF) 100–1
Plasma Protein Therapeutics Association (PPTA) 329
plasma volume, restoration 95
platelet concentrates (PLT) 343
aggregates 48
bacterial quality control 117–18
293, 294
manufacture 41, 42
outgassing 48
transportation 59, 124
policies, transfusion see guidelines and policies, transfusion
poor seals in blood product manufacture 48
post-donation information, donor 27, 27, 27–8
post-operative cell salvage 308–9
post-transfusion purpura (PTP) 9, 284, 284, 356
PPTA (Plasma Protein Therapeutics Association) 329
pregnancy 134
premises, blood component preparation 39, 104
preoperative collection of autologous blood (PAD) 306–7, 309
preparation of blood components 36–51, 99–112
actions and measures taken 293, 293–5
audits 48–9, 108–9
developing countries 263
documentation 40, 105
documentation of jobs 44–5, 107–8
equipment/machinery 39, 103, 103–4
error management 43, 48, 103, 104, 105–7, 106
improvement procedures 49–50, 109–11, 110, 111
monitoring and assessment 45–9, 108, 108–9
planning 40
premises 39, 104
products and processes 38–44, 100–7
quality control 45–9, 105
quality indicators 46–8
quality management systems 40, 45–50, 101, 101, 104–5
risk management 105–7
standards and specifications 38–9, 100–7
starting materials/incoming goods 39, 41, 101–3
training and assessment 50
prescribing 65–6, 139–40
pre-transfusion testing 52 testing, pre-transfusion
processing, blood see preparation of blood components
production segment
actions and measures triggered 293, 293–5
developing countries 262–4
outcomes and achievements 296, 297
risks and problems identified 289–90, 290
see also blood establishments; preparation of blood components
product/process vigilance 12
blood donation 21–2, 78–83
developing countries 267
medical decision and ordering 52
preparation of blood components 38–44, 100–7
see also quality management systems
professional organizations, governance role 15
professional responsibility 139–40
proportionality principle 236
Pseudomonas putida 215
publication, donor vigilance reports 92
Public Health Agency of Canada (PHAC) 193–4, 200
biovigilance system 335
data flow 195, 195
international collaboration 275, 276
National Working Party for Data Review (NWPPDR) 196–8
public health authority, governance role 15
Public Health Services of the United States of America (USPHS) 257, 275, 328
public–private partnerships (PPP) 338
purine analogs 67
quality assurance
preparation of blood components 105
screening of donations for infection 114
quality control
blood group serology-compatibility testing 118
developing countries 267
blood product 45–9, 105
quality improvement
blood component preparation 49–50
donor hemovigilance 53–4
quality indicators
blood product 46–8
testing for infection, Greek system 55, 56
quality management systems (QMS)
blood establishments 294
blood group serology-compatibility testing 118
developing countries 263, 265, 267
European requirements 242–3
integration of hemovigilance 6, 6–7, 13
quality system: see quality management systems
quarantine 43–4, 116, 121
Queensland Blood Management Program (QBMP) 212, 213
Queensland Incidents in Transfusion (QIT) 212–13
rapid alert system (RAS) 15–16, 258
Arab Hemovigilance Network 230
European Union 247–9
International Hemovigilance Network 15–16, 255
rate 346
recipients
adverse events see adverse events, in recipients
adverse reactions see transfusion reactions
defined 344
identification see identification, recipient
information provision to 69, 128
initial focus on 12
monitoring during transfusion 69–71, 71, 129, 136
preparation for transfusion 69
pre-transfusion sample collection see sample collection
record keeping see documentation
red blood cell concentrate (RBC) 343
clots 48
manufacture 41
outdating 48
red cell antibodies, compatibility testing 119
red cell salvage see peri-operative cell salvage
refrigerators 58
computer-based access 138
Regional Blood Centers/Authorities (RCs), Italian 204, 205
Regional Hemovigilance Coordinators (RHC), French system 150
regional hemovigilance systems 8
Arab Hemovigilance Network 226–32
Australia 210, 211–13
donor vigilance 84–6, 85
establishing 228–32
requirements 227
registration, drug 105
release of blood components 43–4, 121, 121–2
documentation 108, 121–2
Greek requirements 58
notification of adverse events 122–3
reporting establishments 113
reporting of events
Arab Hemovigilance Network 227, 228–30
Australia 211–15
blood component manufacture 43, 49, 105, 106
blood group serology-compatibility testing 119–20
Canada 193, 194–6, 195, 198–201
clinical transfusion errors 127–8, 141
developing countries 265–7, 266
donor adverse reactions 25, 31–2
donor care errors (incidents) 26
donor vigilance systems 88–92, 89
Dutch TRIP 180, 181–2, 182
European experiences 244–7, 246, 248
European requirements 238, 241–2
France 150–1
Greece 53
inappropriate transfusions 64, 66
integration into hospital incident reporting system 66, 66
issuing blood components 122–3
Italy 205–7
Japan 160–2
legal requirements 15
no-fault (blame-safe) 14, 26, 256
scope 13, 13
structures 14
transfusion-transmitted bacterial infections 118
transfusion-transmitted infections 117
UK SHOT scheme 169–74
United States 221–5, 329–30
respiratory transfusion complications 291
see also transfusion associated circulatory overload
transfusion associated dyspnea; transfusion-related acute lung injury
results of hemovigilance see achievements through hemovigilance
Retrovirus Epidemiology Donor Studies (REDS-I and REDS-II) 337
return of blood components 99
auditing 68, 68
RhD blood typing 118–19
errors 119–20
Rhesus negative blood products, guidelines for use 63
risk management, blood component production 105–7
risks, transfusion 322
Royal Children’s Hospital, Melbourne, transfusion guideline 65–6
Royal College of Pathologists of Australasia (RCPA) 210, 215
378  Index

SABRE (Serious Adverse Blood Reactions and Events), UK 169, 173
Safety Supervision Unit, Japanese system 160, 161, 162, 164–6
St George’s Hospital, London implementing clinical guidelines 66–8
reporting transfusion incidents 66, 66
sample collection
achievements of hemovigilance 298
errors in Canada 199, 199
pre-transfusion testing 128, 132–3
sampling, blood product, for quality control 46
Sanquin, the Netherlands 180, 181
Scottish National Blood Transfusion Service (SNBTS) 168–9, 172
screening, pre-transfusion see testing, pre-transfusion
screening tests, transfusion-transmitted infections 114
Séminaire Européen des systèmes d’Hémovigilance, 1er (1997) 253
sentinel surveillance systems 150, 326, 327
Australia 211–12, 213
United States 221, 224–5
separators, blood component 108, 108, 109
Serious Adverse Blood Reactions and Events (SABRE), UK 169, 173
serious adverse events (SAEs) 55
serious adverse reactions (SARs) 55
screening tests, transfusion-transmitted infections 114
Serious Hazards of Transfusion (SHOT) 55
Serious Hazards of Transfusion (SHOT) scheme, UK 8, 168–79
achievements 10, 284–8, 289
annual reports 177–8
autologous transfusion 171, 309, 314–18, 317, 318, 319
decentralized structure 15
error-based adverse incidents 127, 127–8, 128
governance 174–5
impact of EU Blood Directive 173–4
infrastructure and budget 176
launch 176–8
main characteristics 169–76, 170
management structure 176, 176
origins 168–9
participation 174
recommendations 140, 177–8, 285–8
relationship with other professional bodies 175
reporting categories 129, 169–72, 170
reporting system 172–3
scope 172–3
Serious Transfusion Incident Reporting (STIR) system, Australia 211–12, 217
severe adverse events see serious adverse events
severe adverse reactions see serious adverse reactions
severe allergic or anaphylactic reactions (SAAR), Canada 196, 197
severity of adverse reactions defined 345
in donors, grading 349–50, 366–7
in recipients
Dutch TRIP system 183, 183, 183–4
French grading system 151
ggrading 347, 358
shipping containers 58–9, 123
SHOT see Serious Hazards of Transfusion Singapore
government 15
guidelines for appropriate transfusion 63
SISTRA (Sistema Informativo dei Servizi Trasfusionali) 204–5
SKAE see Hellenic Coordinating Haemovigilance Centre
Société Française des Vigilance et de Thérapeutique Transfusionnelle (SFVTT) 151
Society of Thoracic Surgeons Blood Conservation Guideline Task Force, UK 62
SOPs see standard operating procedures
South Australia (SA) BloodSafe program 213
special requirements not met (SRNM) 134, 171
Spongiform Encephalopathy Advisory Committee (SEAC), UK 175
staff see personnel
standard operating procedures (SOPs) blood administration 69
blood component preparation 40, 103, 104
donor vigilance 30, 96
French system 152–3
medical decision and ordering 66
surgical blood ordering 68
standards, transfusion see guidelines and policies, transfusion
Standard Work Instruction Manual (SWIM), Transfusion Ontario 66
starting materials, preparation of blood components 41, 101–3
Stem Cell Therapeutic Outcomes Database (SCTOD) 337
storage 44
adverse events related to 113
autologous blood donations 310
developing countries 264
errors 43
Greek requirements 58
premises 39
stratified analysis, donor vigilance data 90
subsidiarity principle 236
Substances of Human Origin (SOHO), vigilance and surveillance 335
surgical blood ordering schedules 68
surveillance 149–50, 326–7
active or hot 150, 326
clinical effectiveness of transfusion 322–5
passive or cold 150, 326
Surveillance and Epidemiology of Transfusion (SET) Working Group, Canada 194
survival, transfusion recipients 323
syncope see vasovagal reactions
syphilis 116
system model, hemovigilance 281, 282
TACO see transfusion associated circulatory overload
temperature
auto-sterilization of whole blood 102
storage 58
transportation 59, 123
tendon injury 348, 364
testing, pre-transfusion 113–21
adverse events related to 113
bacterial quality control 117–18
blood group serology-compatibility 56–7, 118–21
error management 120–1
ersors 118, 119–20
Greek guidelines 56–7
hemovigilance procedures 57
hemovigilance procedures 119
quality issues 118–19
developing countries 263
sample collection 128, 132–3
transfusion transmissible infections 54–5, 114–17
epidemiological surveillance 54–5, 115, 115–16
hemovigilance procedures 114–17
participation rates 35
protocol 54–5
quality measures and test validation 114
Therapeutic Goods Administration (TGA), Australia 210, 214, 215
thrombophlebitis 348, 364
Tissue and Organ Surveillance System (TOSs), Canada 335
TissueNet, US 335–6
traceability 37, 345
European requirements 237–8, 241
French system 151, 152, 153
Greek system 56
human cells, tissues, and their products (HCT/Ps) 332–3
implementation within hospital 67, 68
Japanese system 163, 165, 166
labeling 42
manufacturing processes 41, 42, 43, 99–100
potentially infectious donations 116–17
donors’ transportation 123
WHO emphasis 275
traffic light visualization systems 107
training (and education)
clinical transfusion activities 68, 130
blood administration 69–70, 137–8
sample collection 133
UK 137–8
developing countries 269
donor hemovigilance 33
TRALI see transfusion-related acute lung injury
tranexamic acid 313
transfusion see blood transfusion
transfusion associated circulatory overload (TACO) 9
acute hypervolemic hemodilution 307
Canada 196–6, 197
case study 130
definition 357
France 154–6, 157
the Netherlands 187
UK SHOT scheme 171
transfusion associated dyspnea (TAD) Canada 196, 197
definition 357
UK SHOT scheme 171
transfusion associated graft-versus-host disease (TA-GVHD) 9, 291
definition 356
Japan 159
outcomes of hemovigilance 285, 298
prevention methods 294
UK SHOT 284, 284, 285
transfusion committees, hospital see hospital transfusion committees
Transfusion Errors Surveillance System (TESS), Canada 198–200, 199, 201
transfusion forms 123
Transfusion Incident Reports (TIR) French system 150–1
rates 152, 152
transfusion medicine education 137
Transfusion Ontario Standard Work Instruction Manual (SWIM) 66
transfusion practitioner, hospital 64, 65
transfusion reactions (adverse reactions in recipients) 7, 9
achievements of hemovigilance 297–8
Canadian system 195–6, 196
definitions 346
developing countries 263–7, 266
Dutch TRIP system 181, 182, 182–9, 183
imputability see imputability, recipient adverse events
infectious see transfusion-transmitted infections
Japanese rates 165, 165
Japanese system 161–3, 164
non-infectious 346
patient monitoring 70–1, 71, 136–7
UK SHOT scheme 172–7
proposed standard definitions (ISBT) 351–9
severity grading 347, 358
Dutch TRIP 183
French system 151
UK SHOT scheme 172
under-reporting 137
Transfusion Reactions in Patients (TRIP), the Netherlands 10, 180–90
bacterial contamination concerns 117
governance 15
participation 181, 181
reports received 181–2, 182
results 2003–2009 182, 182–9, 183
imputability 184, 184
obligatory reports of serious adverse events 186, 186
severity of transfusion reactions 183, 183, 183–4
specific reactions and incidents 186–9
by type of blood component supplied 185, 185
variation among hospitals 184–5, 185
transfusion-related acute lung injury
(TRANSALI) 9
achievements of hemovigilance 298
Australia 214
Canada 196, 197
definition 356
Dutch TRIP 186, 186–7
European reports 246, 246
France 154–6, 157
Japan 165
prevention 10, 41
the Netherlands 186, 186–7
New Zealand 292–3
UK SHOT recommendations 285–6
UK SHOT scheme 173, 284
transfusion specialist 64
transfusion-transmitted bacterial infections (TTB) 9, 346
achievements of hemovigilance 297–8
Australia 214–15
prevention at manufacturing stage 41–2
preventive actions 294
quality control testing 117–18
see also bacterial contamination
transfusion-transmitted infections (TTIs) 9, 346
achievements of hemovigilance 297–8
investigation of potential 116–17
Italian system 206–7
Japanese system 162–3
prevention during processing 41–2
rates in Greece 115, 115–16, 116
risks and problems 290
testing 54–5, 114–17
epidemiological protocol 54–5
epidemiological surveillance 54–5, 115, 115–16
hemovigilance procedures 114–17
participation rates 55
quality measures and test validation 114
tracing and retrieval of infected donations 116–17
UK SHOT recommendations 288
UK SHOT reporting 173, 284
see also look-back procedures; traceability
Transfusion Transmitted Injuries Surveillance System (TTISS), Canada 194–6, 201
participation 196–8, 198
transfusion-transmitted non-bacterial infections (TTNBI), France 152, 155
transfusion-transmitted parasitic infections (TTP) 9, 346
transfusion-transmitted viral infections (TTVI) 9, 346
achievements of hemovigilance 297
Japan 165, 165–6
preventive actions 293–4
transplantation
biovigilance in US 331–4
development of vigilance and surveillance systems 334–7
mandating biovigilance 339
regulation/oversight in US 330–1
risks 327–8
Transplantation Transmission Sentinel Network (TTSN), US 224–5
transportation 123–4
developing countries 264
Greek requirements 58–9
quality requirements 123–4
traceability during 123
TRIP see Transfusion Reactions in Patients
type and screen procedure 119
see also blood group
serology-compatibility testing
unclassifiable complication of transfusion (UCT) 358
Uncontrolled Donation after Circulatory Death (UDCD) 334
Index

under-reporting, recipient adverse events 137
undertransfusion 64, 131–2
UK SHOT scheme 171
United Kingdom (UK)
achievements of hemovigilance 284–8
hemovigilance system 168–79
National Comparative Audits 136–7
national transfusion guidelines and protocols 138
SHOT scheme see Serious Hazards of Transfusion (SHOT) scheme
transfusion education and training 137–8
United Kingdom Cell Salvage Action Group (UKCSAG) 314, 316
United Network for Organ Sharing (UNOS), US 224, 225, 330
United States (US)
biovigilance 220–5, 328–33, 335–7
background of need 327–8
human cells, tissues and product (HCT/Ps) 331–3
solid organ transplantation 333–4
Donor Hemovigilance System 86–8, 87, 88, 90, 223–4
transfusion recipient surveillance 221–3
Transplantation Transmission Sentinel Network (TTSN) 224–5
usage segment
actions and measures taken 295, 295–6
developing countries 264, 264–5
outcomes and achievements 296, 297
risks and problems identified 290–2, 291
see also clinical transfusion activities: hospitals
validation
donor vigilance data 30–1, 31, 86, 87
IT systems for blood product preparation 104
pre-transfusion screening tests 114
vascularized composite allografts (VCA) 334
vasovagal reactions 348–9, 364–5
delayed 23, 24–5, 365
donor position and 90
grading of severity 366
potential predictors 95
prevention 94, 96
venipuncture 81
Vie Médicale, La (magazine) 149
vigilance, defined 326
vigilance and surveillance (V&S) systems, cells, tissues and organs 334–7
VIIa, recombinant 313–14
viral infections, transfusion-transmitted see transfusion-transmitted viral infections
visual inspection
before issuing 122, 123
before processing 41, 102–3
before transportation 123
volunteers, donor hemovigilance systems 30
Welsh Blood Service (WBS), surveillance of red cell salvage 314–16, 315
WHO see World Health Organization
whole blood (WB) 343
centrifugation 41
collection 77, 81, 82
incoming units, for processing 41, 102–3
separation 41
World Health Assembly (WHA) 270
resolutions on blood safety 202, 271, 272
World Health Organization (WHO) 38, 256–7, 270–6
aims and responsibilities 271, 271–2, 273
biovigilance activities 335
Blood Safety Standards 273
Blood Safety Unit 271
Blood Transfusion Safety (BTS) program 271, 272–5
developing policies for clinical use of blood 62–3
framework 270–1
Global Collaboration for Blood Safety (GCBS) 202, 256–7, 275
Global Database on Blood Safety 261, 262, 274
hemovigilance in developing countries 274–5
publications 273–4
Safe Blood Policy 272
Safe Transfusion Practice 273
wrong blood events, laboratory errors 119–20
wrong blood in tube (WBIT) 347
case studies 133
causes 133
UK SHOT scheme 171
wrong name on tube (WNOT) 347